

Immunologist: Pfizer, Moderna Vaccines Could Cause Long-Term Chronic Illness

By <u>Children's Health Defense</u> Global Research, February 10, 2021 <u>Children's Health Defense</u> 9 February 2021 Region: <u>USA</u> Theme: <u>Science and Medicine</u>

All Global Research articles **can be read in 27 languages by activating the "Translate Website"** drop down menu on the top banner of our home page (Desktop version).

In new research published in Microbiology & Infectious Diseases, immunologist **J. Bart Classen** warns the mRNA technology used in the Pfizer and Moderna COVID vaccines could create "new potential mechanisms" of adverse events that may take years to come to light.

Back in 1999, leading U.S. Food and Drug Administration (FDA) official Dr. Peter Patriarca <u>contended</u> that modern advances in vaccine technology were rapidly "outpacing researchers' ability to predict potential vaccine-related adverse events." Patriarca mused that this could lead to "a situation of unforeseen and unpredictable vaccine outcomes."

In a new <u>research article</u> published in Microbiology & Infectious Diseases, veteran immunologist J. Bart Classen expresses similar concerns and writes that "RNA-based <u>COVID</u> <u>vaccines</u> have the potential to cause more disease than the epidemic of COVID-19."

For decades, Classen has published papers exploring how vaccination can give rise to chronic conditions such as <u>Type 1</u> and <u>Type 2</u> diabetes — not right away, but three or four years down the road.

In this latest paper, Classen warns that the <u>RNA-based vaccine technology</u> could create "new potential mechanisms" of <u>vaccine adverse events</u> that may take years to come to light.

<u>Classen's study</u> establishes the potential for the messenger RNA (mRNA) vaccines developed by <u>Pfizer</u> and <u>Moderna</u> to activate human proteins to take on "pathologic configurations" — configurations associated with chronic degenerative neurological diseases. Although his specific interest is in <u>prion diseases</u> (conditions associated with misfolded versions of normal proteins), Classen also outlines a handful of other mechanisms whereby RNA-based vaccines could give rise to "multiple other potential fatal adverse events."

Ensuring that patients <u>clearly understand</u> risks — including known risks as well as <u>potential</u> <u>unknown risks</u> — is an important component of the <u>informed consent</u> process. This is all the more true when the intervention is experimental and lacks long-term safety data, as is the case with the Pfizer and Moderna vaccines against COVID-19. The FDA authorized the two

vaccines for widespread emergency use based on just two months of clinical trial data.

Unfortunately, it is not unusual for researchers' communication of risks to be <u>perfunctory</u>. In October, researchers at New York University and Tulane <u>reported</u> that the information communicated to participants in the coronavirus clinical trials about a worrisome problem known as <u>pathogenic priming</u> was "sufficiently obscured" as to make "adequate patient comprehension" of risks "unlikely."

It would be interesting to know what those researchers would say about Classen's blunt conclusion that "Approving a vaccine, utilizing novel RNA technology without extensive testing is extremely dangerous."

Those contemplating COVID injections may be ignoring potential risks at their own peril.

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from CHD

The original source of this article is <u>Children's Health Defense</u> Copyright © <u>Children's Health Defense</u>, <u>Children's Health Defense</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Children's Health Defense

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca